Press Releases

Press Releases

    Date Title View
    07/22/20
    Summary ToggleTarget Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance Response Rates for People Living with Uncontrolled Gout
    PDF Version
    07/13/20
    Summary ToggleHorizon Therapeutics plc to Release Second-Quarter 2020 Financial Results and Host Webcast on Aug. 5, 2020
    PDF Version
    07/09/20
    Summary ToggleCenters for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for TEPEZZA® (teprotumumab-trbw) Effective Oct. 1, 2020
    PDF Version
    07/01/20
    Summary ToggleNew Initiative Encourages the Graves’ Disease Community to FOCUS on Eye Health
    PDF Version
    06/03/20
    Summary ToggleHorizon Therapeutics plc Announces Redemption of All $400 Million of Its Exchangeable Senior Notes
    PDF Version
    06/03/20
    Summary ToggleData Presented on KRYSTEXXA® (pegloticase injection) Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach
    PDF Version
    05/21/20
    Summary ToggleHorizon Therapeutics Named Number One Best Workplace in Chicago
    PDF Version
    05/21/20
    Summary ToggleData on Multiple Immunomodulation Approaches with KRYSTEXXA® (pegloticase injection) to be Presented at the Annual European Congress of Rheumatology (EULAR 2020)
    PDF Version
    05/19/20
    Summary ToggleHorizon Therapeutics to Participate in Upcoming Investor Conferences
    PDF Version
    05/14/20
    Summary ToggleNew Data on the Pharmacokinetic Profile of TEPEZZA™ (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy
    PDF Version
    Displaying 11 - 20 of 521 results